Our goal is to address this under-representation of minorities, and compare pCR rates seen in our predominantly Hispanic population at Olive View-UCLA Medical Center (OVMC) being treated for HER2-positive breast cancer with those who were treated in TRYPHAENA trial. Here, ERBB2 is linked to breast carcinoma.